{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:40:17Z","timestamp":1791510017211,"version":"4.3.4"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Acitretin is a widely used systemic retinoid in the treatment of psoriasis. Dosage of acitretin in not weight adjusted due to certain interindividual variations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate the clinical efficacy and effects on biochemical parameters of fixed tapering dosage of acitretin in patients with psoriasis administered over a period of 4 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This was an observational study. The study included patients of psoriasis vulgaris in the age group of 18 and 65 years with a psoriasis area severity index (PASI) score of &gt;10 which was not responsive to topical therapy and phototherapy. Patients were given oral acitretin daily at a dose of 25 mg BD for 2 weeks, which was later tapered to 25 mg OD for another 2 weeks. The clinical efficacy and biochemical parameters were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Out of the 18 patients, PASI 75 was achieved in 66% of the patients by the end of the third week. Significant elevations were noted in serum lipids during 4 weeks, which returned to normal limits or near baseline levels at the end of 4 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Fixed tapering dose of acitretin is effective in psoriasis with minimal clinical and biochemical adverse events<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijd.ijd_300_18","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T05:11:28Z","timestamp":1559020288000},"page":"213-216","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Fixed Tapering Dosage of Acitretin in Patients with Psoriasis: A Short-Term Analysis of Clinical Efficacy and its Effects on Biochemical Parameters"],"prefix":"10.4103","volume":"64","author":[{"given":"Varadraj V","family":"Pai","sequence":"first","affiliation":[{"name":"From the Department of Dermatology, Venereology and Leprosy, Goa Medical College, Bambolim, Goa, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diksha","family":"Phadke","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Venereology and Leprosy, Goa Medical College, Bambolim, Goa, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Shukla","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Venereology and Leprosy, Goa Medical College, Bambolim, Goa, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krupeksha","family":"Naik","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Venereology and Leprosy, Goa Medical College, Bambolim, Goa, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250921","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1111\/j.1468-3083.2012.04644.x","article-title":"Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: A randomized, double blind, parallel group, dose ranging study","volume":"27","author":"Dogra","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R2-20250921","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/535612","article-title":"Lipid Disturbances in Psoriasis: An Update","volume":"2010","author":"Pietrzak","year":"2010","journal-title":"Mediators Inflamm"},{"key":"R3-20250921","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/pde.12940","article-title":"Effectiveness and safety of acitretin in children with plaque psoriasis: A multicenter retrospective analysis","volume":"33","author":"Di Lernia","year":"2016","journal-title":"Pediatr Dermatol"},{"key":"R4-20250921","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ad.2013.01.003","article-title":"Guidelines for the use of acitretin in psoriasis. Psoriasis group of the Spanish Academy of Dermatology and Venereology","volume":"104","author":"Carretero","year":"2013","journal-title":"Actas Dermosifiliogr"},{"key":"R5-20250921","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/j.1365-2133.2010.09755.x","article-title":"British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology","volume":"162","author":"Ormerod","year":"2010","journal-title":"Br J Dermatol"},{"key":"R6-20250921","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0190-9622(96)80148-4","article-title":"Prooceedings of the psoriasis combination and rotation therapy conference","volume":"34","author":"Menter","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"R7-20250921","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2133.1987.tb04140.x","article-title":"Treatment of severe psoriasis with etretin (RO 10- 1670)","volume":"117","author":"Lassus","year":"1987","journal-title":"Br J Dermatol"},{"key":"R8-20250921","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-2133.2005.06906.x","article-title":"Oral retinoid therapy for disorders of keratinization: Single-centre retrospective 25 years\u2019 experience on 23 patients","volume":"154","author":"Katugampola","year":"2006","journal-title":"Br J Dermatol"},{"key":"R9-20250921","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000247462","article-title":"Overexpression of cellular retinoic acid-binding protein type II (CRABP-II) and down-regulation of CRABP-I in psoriatic skin","volume":"185","author":"Siegenthaler","year":"1992","journal-title":"Dermatology"},{"key":"R11-20250921","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0190-9622(88)70198-X","article-title":"Acitretin versus etretinate in psoriasis-clinical and pharmacokinetic results of a German multicentre study","volume":"19","author":"Gollnick","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"R12-20250921","first-page":"35","article-title":"A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis - results of a Nordic multicenter study","volume":"69","author":"Kragballe","year":"1989","journal-title":"Acta Derm Venereol (Stockh)"},{"key":"R13-20250921","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S0190-9622(89)70138-9","article-title":"Side-effect profile of acitretin therapy in psoriasis","volume":"20","author":"Gupta","year":"1989","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl","key":"R14-20250921","first-page":"S111","article-title":"Pustulosis palmo-plantaris. Clinical and histological changes during acitretin therapy","volume":"146","author":"Schroder","year":"1989","journal-title":"Acta Derm Venereol (Stockh)"},{"key":"R15-20250921","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0190-9622(99)70359-2","article-title":"Acitretin in psoriasis: An overview of adverse effects","volume":"41","author":"Katz","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"R16-20250921","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archderm.142.8.1000","article-title":"Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis","volume":"142","author":"Pearce","year":"2006","journal-title":"Arch Dermatol"},{"key":"R17-20250921","doi-asserted-by":"crossref","first-page":"f5961","DOI":"10.1136\/bmj.f5961","article-title":"Risk of moderate to advanced kidney disease in patients with psoriasis: Population based cohort study","volume":"347","author":"Joy","year":"2013","journal-title":"BMJ"},{"issue":"Suppl 2","key":"R18-20250921","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1681\/ASN.2005121320","article-title":"Lipids and renal disease","volume":"17","author":"Trevisan","year":"2006","journal-title":"J Am Soc Nephro"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00076423-201964030-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:42:21Z","timestamp":1787067741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00076423-201964030-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_300_18","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"2018-07-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}